

**09:00 – 09:30**

### **Networking breakfast and partnering**

**Gallery Level and Music Foyer**

Grab a #BIGIMPACT coffee and start connecting with the BIA TechBio community.

**09:30 – 10:50**

### **Parallel workshop – When and how to think about cybersecurity as a techbio?**

**Hall One**

Cybersecurity is a growing challenge for all companies, but particularly for those in sectors like ours where IP and data make up a significant component of a company's value.

However, many are relatively unprepared for the task, and as such may be vulnerable. Join this expert workshop to learn more about why you should consider cybersecurity early in your company journey, and what can be done to protect yourself moving forwards.

**09:30 – 10:50**

### **Parallel workshop – Level up your compensation game**

**Hall Two**

We invite you to join Jody Thelander, Founder & CEO, of the namesake firm and Morgan Thelander, COO, for an in-depth session on global compensation and strategies for privately held companies across life sciences and tech. The Thelander team will share exclusive real time data, insights and analysis on all aspects of compensation, including, but not limited to:

- How cash and equity compensation in the UK and US compare and contrast
- Option pool by total amount of financing and industry
- Equity awards, what type of equity to grant, when to refresh and how that fits into your option pool

**11:00 – 11:15**

### **Welcome and opening keynote**

**Hall One**

Come and hear from Ramesh Durvusala, Senior Vice President for R&D IT at Eli Lilly & Company, as he shares his perspective on how techbio will influence pharma and the sector.

**11:15 – 12:15**

### **Question Time: The state of TechBio in the UK**

**Hall One**

The TechBio landscape has continued to evolve rapidly in the last year. Join us as we discuss the lessons we have learned, and look ahead to what we expect to see in future. There will also be an opportunity to get answers to questions you may have about the broader picture of data driven life science in the UK.

The TechBio landscape has continued to evolve rapidly in the last year. Join us as we discuss the lessons we have learned, and look ahead to what we expect to see in future. There will also be an opportunity to get answers to questions you may have about the broader picture of data driven life science in the UK.

**12:15 – 13:00**

### **Investment for TechBio companies**

**Hall One**

For some, the last few months have been a time of exciting deals, while others have continued to face a challenging financial environment. In this session we will look at where the money is coming from in the second half of 2024, and how you can best set yourself up for success.

**13:00 – 14:15**

### **Networking lunch**

**Gallery Level and Music Foyer**

Enjoy delicious food while making valuable connections with industry leaders, innovators, and potential collaborators.

**14:15 – 15:00**

### **At the cutting edge: Company showcases**

Come and hear from 5 of the most exciting organisations working in this space as they walk us through their achievements, and how they will change the landscape. Vote for the one you think will have the greatest impact to give them a chance to speak again in the final plenary session.

**Hall One**

**AI & data track**

**Hall Two**

**Engineering biology track**

**St Pancras Room**

**Genomics track**

**15:15 – 16:00**

### **Panel discussions**

#### **AI & data track: Spinning out vs building up – lessons from different approaches to AI companies**

**Hall One**

There are broadly two different approaches to developing thriving life science AI companies – spinning out from larger organisations, or launching as a new start-up. This session will compare the pros and cons of both approaches, and see if there's common lessons to be learned for building a successful company. We'll also dig into what both approaches can teach from a culture and operational perspective.

#### **Engineering biology track: What lessons can therapeutic engineering biology teach other sectors?**

**Hall Two**

Engineering biology has a long and proud history in therapeutic development, leading to a number of success stories. However, recently engineering developments outside healthcare have drawn a lot of interest, and these "deep biotech" solutions promise to help address an entirely different landscape of challenges. Join this session as we discuss what lessons these newer companies may be able to learn from their therapeutic forbears, and where their solutions must differ.

#### **Genomics track: Beyond genomics – delivering on applications of multiomics**

**St Pancras Room**

For a number of years now, multiomic approaches have promised to revolutionise healthcare monitoring and drug discovery, and we are now entering a phase where many of these promises are starting to be delivered. Join us for a discussion of where the current state of the art is, and what remaining challenges need to be addressed for multiomics to deliver its full potential.

**16:00 – 16:30**

### **Networking break**

**Gallery Level and Music Foyer**

Recharge with a #BIGIMPACT coffee and continue conversations with the BIA TechBio community.

**16:30 – 16:15**

### **At the cutting edge: Company showcase favourites**

**Hall One**

The audience favourite company from each track will deliver their pitch to the whole conference. Come and get a sample of what exciting developments took place in the other tracks.

**17:15 – 17:30**

### **Closing remarks and keynote**

**Hall One**

Sergei Yakneen, Chief Technology Officer of Isomorphic Labs, will discuss how new tools are enabling a new generation of biotech solutions.

**17:30 – 20:00**

### **Networking drinks reception**

**Hall Two**

Join us for canapes and a glass of something cold plus lots more excellent networking.